93 related articles for article (PubMed ID: 8427565)
1. Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease.
Omar R; Pappolla M; Argani I; Davis K
Arch Pathol Lab Med; 1993 Feb; 117(2):166-9. PubMed ID: 8427565
[TBL] [Abstract][Full Text] [Related]
2. MAP-2 immunolabeling can distinguish diffuse from dense-core amyloid plaques in brains with Alzheimer's disease.
D'Andrea MR; Nagele RG
Biotech Histochem; 2002 Mar; 77(2):95-103. PubMed ID: 12083391
[TBL] [Abstract][Full Text] [Related]
3. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease.
Pappolla MA; Omar RA; Kim KS; Robakis NK
Am J Pathol; 1992 Mar; 140(3):621-8. PubMed ID: 1372157
[TBL] [Abstract][Full Text] [Related]
5. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
7. Regression stage senile plaques in the natural course of Alzheimer's disease.
Oide T; Kinoshita T; Arima K
Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888
[TBL] [Abstract][Full Text] [Related]
8. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
9. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
10. Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density.
Mochizuki A; Peterson JW; Mufson EJ; Trapp BD
Exp Neurol; 1996 Nov; 142(1):89-102. PubMed ID: 8912901
[TBL] [Abstract][Full Text] [Related]
11. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
12. Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
Kar S; Poirier J; Guevara J; Dea D; Hawkes C; Robitaille Y; Quirion R
Neurobiol Aging; 2006 Feb; 27(2):199-210. PubMed ID: 16399207
[TBL] [Abstract][Full Text] [Related]
13. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
14. Plaques of Alzheimer's disease originate from cysts of Borrelia burgdorferi, the Lyme disease spirochete.
MacDonald AB
Med Hypotheses; 2006; 67(3):592-600. PubMed ID: 16675154
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
16. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
17. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
Kuhla B; Boeck K; Schmidt A; Ogunlade V; Arendt T; Münch G; Lüth HJ
Neurobiol Aging; 2007 Jan; 28(1):29-41. PubMed ID: 16427160
[TBL] [Abstract][Full Text] [Related]
18. [A comparative study on histopathological findings between Alzheimer's disease and senile dementia of Alzheimer type].
Nakamura N
Rinsho Byori; 1996 Mar; 44(3):225-30. PubMed ID: 8857164
[TBL] [Abstract][Full Text] [Related]
19. Brain site-specific gene expression analysis in Alzheimer's disease patients.
Yokota T; Mishra M; Akatsu H; Tani Y; Miyauchi T; Yamamoto T; Kosaka K; Nagai Y; Sawada T; Heese K
Eur J Clin Invest; 2006 Nov; 36(11):820-30. PubMed ID: 17032350
[TBL] [Abstract][Full Text] [Related]
20. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
